Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Increased by Citizens Financial Group Inc. RI

Key Points

• Citizens Financial Group increased its Regeneron stake by 36.6% in the third quarter, bringing its holdings to 5,978 shares worth approximately $4.53 million. Institutional investors collectively own 83.31% of REGN.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $846.28; several firms recently raised their targets, including JPMorgan to $950 and TD Cowen to $980.
• Regeneron reported quarterly earnings of $14.29 per share versus the $10.16 estimate, while revenue rose 16.7% year over year to $4.29 billion. However, insiders sold 8,093 shares worth about $6.5 million over the past 90 days, and valuation concerns remain ahead of the next earnings release.

Citizens Financial Group Inc. RI boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 36.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,978 shares of the biopharmaceutical company's stock after purchasing an additional 1,602 shares during the quarter. Citizens Financial Group Inc. RI's holdings in Regeneron Pharmaceuticals were worth $4,533,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $5,682,636,000. Legal & General Group Plc acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. Bank of New York Mellon Corp purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $472,950,000. Deutsche Bank AG acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $323,249,000. Finally, Man Group plc purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $272,460,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director directly owned 603 shares of the company's stock, valued at $512,550. The trade was a 39.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares of the company's stock, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on REGN shares. Zacks Research raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, September 28th. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 6th. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Sanford C. Bernstein boosted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a "market perform" rating in a research note on Friday, August 14th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $846.28.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $805.02 on Monday. The firm has a market cap of $82.88 billion, a P/E ratio of 19.90, a P/E/G ratio of 1.36 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $575.93 and a fifty-two week high of $859.34. The business has a 50-day moving average price of $791.86 and a 200 day moving average price of $722.88. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the prior year, the business earned $12.81 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.